WednesdayFeb 28, 2024 9:45 am

Siteman Cancer Center Starts Offering Novel Cell-Based Immunotherapy Against Melanoma

Patients with melanoma may soon be able to access a new immunotherapy that was recently approved by the U.S. Food and Drug Administration (FDA). The cell-based treatment, which was developed by Iovance Therapeutics, will first be administered by physicians at the Siteman Cancer Center in Washington University before it can be commercialized under the name Amtagvi. The tumor-infiltrating lymphocyte immunotherapy has been designed for the treatment of metastatic melanoma, which is a skin cancer that has spread to other parts of the body. The treatment, called lifileucel, has been designed specifically for patients suffering from this particular cancer whose tumor…

Continue Reading

TuesdayFeb 27, 2024 12:00 pm

Astiva Health Inc. Championing Culturally Sensitive Healthcare for Aging Asian American Population

By 2060, the older Asian population in the U.S. is expected to reach 8.5 million, making up 9% of the country's elderly demographic, signaling a significant increase from 4% in 2014 Astiva Health is leading the charge in creating essential healthcare solutions tailored for this expanding demographic, demonstrating a deep understanding of their unique healthcare needs Astiva Health has introduced groundbreaking programs, including language-specific healthcare services and wellness initiatives, specifically designed for the diverse aging Asian American community Astiva Health is working serve the Asian American community, which is undergoing a considerable demographic shift, with a growing segment of the…

Continue Reading

TuesdayFeb 27, 2024 11:15 am

Astrotech Corp. (NASDAQ: ASTC) Reports 512% Jump in YTD Revenue

Astrotech reported financial results for the quarter ended December 31, 2023, recording year-to-date revenue of $1,540,000 The company attributed the growth to the successful fulfillment of two significant purchase orders for the TRACER 1000(TM), the world’s first mass spectrometer-based explosive trace detectors (“ETD”), to customers in Romania Astrotech is focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries 1st Detect Corp., AgLAB Inc., Pro-Control Inc., and BreathTech Corp. The company and its subsidiaries are positioned to capitalize on burgeoning markets, including the global mass spectrometry market, expected to grow from an estimated $6.77 billion in…

Continue Reading

TuesdayFeb 27, 2024 10:30 am

Sigyn Therapeutics Inc. (SIGYD) Completes Reverse Stock Split, Releases Year-End Financial Report for 2023

Sigyn's common stock, temporarily trading under the ticker symbol "SIGYD", is set to revert back to its historic symbol "SIGY" on February 29, 2024. The company, as part of its 2023 Year-End Report, summarized its development of medical technologies that target to overcome clearly defined limitations in global health. During 2023, Sigyn expanded its line-up of medical technologies designed to enhance the benefit of cancer therapies. The company’s cancer treatment pipeline now includes ImmunePrep(TM), ChemoPrep(TM), and ChemoPure(TM).   The company believes the successful clinical advancement of Sigyn Therapy(TM) to treat pathogen-associated conditions beyond the reach of drugs, may offer a…

Continue Reading

MondayFeb 26, 2024 9:30 am

Study Shows Troops That Sustain Serious Brain Injuries Have Higher Risk of Brain Cancer

Figures show that brain cancer occurs in less than 1% of the population in America. At least one-third of individuals diagnosed with primary brain cancer tumors survive for at least five years. Those with glioblastoma, a common type of brain cancer, have about a 14% chance of living an additional five years. This is dependent on the age of diagnosis, however. While what causes brain cancer is still unknown, scientists theorize that exposure to ionized radiation may be linked to this illness. Now, new research has found that veterans who experience head injuries have a heightened risk of developing brain…

Continue Reading

FridayFeb 23, 2024 10:30 am

Sigyn Therapeutics Inc. (SIGYD) CEO Discusses Opportunities to Treat Cancer and Drug-Resistant Pathogens in Letter to Shareholders

Sigyn Therapeutics Chairman and CEO James A. Joyce recently provided a letter to shareholders that discussed the company’s therapeutic opportunities, challenges, and decision-making processes The letter overviewed the company’s candidate technologies to enhance the performance of cancer therapies (ImmunePrep(TM), ChemoPrep(TM), and ChemoPure(TM)), and provided an update on Sigyn Therapy(TM), an extracorporeal drug purification technology to address pathogen-associated conditions that are beyond the reach of drugs James A. Joyce, the Chairman and CEO of development-stage medical technology company Sigyn Therapeutics (OTCQB: SIGYD, SIGY), recently discussed the company’s opportunities, challenges, and decision-making processes in a letter to shareholders (https://ibn.fm/wGTqS). The company is currently…

Continue Reading

FridayFeb 23, 2024 10:00 am

Challenges Faced in Upholding Medical Ethics in Safety-Net Healthcare Systems

Safety-net health systems are critical to providing adequate healthcare to underserved populations such as ethnic or racial minorities and uninsured and low-income individuals. A September 2023 Census Bureau report noted that 7.9% of the American population, or 26 million people, were uninsured in 2022. Several studies have also shown that racial and ethnic minorities are more likely to face challenges when trying to access medical care in North America. Black, Hispanic and Asian populations appear to have lower access to health insurance coverage in the United States, with Hispanic individuals reportedly facing more significant barriers to accessing health insurance. Safety-net…

Continue Reading

WednesdayFeb 21, 2024 12:45 pm

Astiva Health Navigating the Future of Healthcare with a Vision for Culturally Responsive Medicare Advantage

Astiva Health’s culturally inclusive approach sets a new precedent in the Medicare Advantage market Enrollment in Medicare Advantage programs is projected to encompass half of all Medicare enrollments by 2024, with Astiva Health leading the charge in service expansion and inclusivity Astiva Health is committed to reshaping healthcare delivery with increased access to quality healthcare for diverse populations In a landscape where more individuals are becoming eligible for Medicare, Astiva Health is carving out a niche as a rapidly growing Medicare Advantage Prescription Drug (“MAPD”) health plan. Astiva stands out by redefining personalized and comprehensive healthcare standards. Reflecting its success, Astiva recently…

Continue Reading

WednesdayFeb 21, 2024 12:00 pm

Sigyn Therapeutics Inc. (SIGYD) Advancing Novel Therapeutic Technologies to Enhance the Benefit of Cancer Therapies, Treat Pathogen-Associated Conditions Beyond the Reach of Drugs

Sigyn Therapeutics has designed a pipeline of medical technologies to improve cancer treatment outcomes by reducing the circulating presence of bloodstream particles that decoy or block the intended delivery of cancer therapies. At present, less than 2% of therapeutic antibodies and chemotherapy doses administered to cancer patients are delivered to tumor cell targets The company has also created a medical technology to reduce the circulating presence of off-target chemotherapy from the bloodstream to reduce patient toxicity and organ damage The company’s lead therapeutic candidate addresses life-threatening conditions that are pathogen-induced and not addressed with drug therapies Sigyn Therapeutics (OTCQB: SIGYD,…

Continue Reading

WednesdayFeb 21, 2024 10:00 am

FDA Grants Florida Permission to Import More Affordable Medicines from Canada

The FDA recently approved a plan that permits the state of Florida to import some drugs from Canada at lower prices than the medications that can be acquired in America. It is a well-known fact that the cost of drugs in the United States is high, with numerous studies finding that in comparison to other developed countries, America spends significantly more on prescription medications. One analysis by the Government Accountability Office determined that the prices of most prescribed medications were almost three times higher in America than in Canada. Various factors help determine the exact amount every patient pays for…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050